Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2021

Accounting Policies [Abstract]

Schedule of Earnings Per Share Basic and Diluted

	Three Months Ended September 30,						Nine Months Ended September 30,
	2021			2020			2021			2020
Net loss attributable to INVO Bioscience common shareholders (numerator)	$	(2,242,783	)	$	(1,771,827	)	$	(6,513,415	)	$	(4,539,100	)
Basic and diluted weighted-average number of common shares outstanding (denominator)		10,463,981			4,946,125			10,267,495			4,932,405
Basic and diluted net loss per common share		(0.24	)		(0.36	)		(0.66	)		(0.92	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The Company has excluded the following dilutive securities from the calculation of fully diluted shares outstanding because the result would have been anti-dilutive:

	As of September 30,
	2021		2020
Options		1,118,911		588,321
Convertible notes and interest		160,591		627,738
Unit purchase options and warrants		216,193		971,568
Total		1,495,695		2,187,627